Latest News and Press Releases

Using Positron Emission Tomography (PET) and radioactively labeled ANYARA, drug concentrations in tumor and normal tissues of individual patients have been measured for the first time, demonstrating...

Genom att använda tekniken Positron Emission Tomography (PET) och radioaktivt inmärkt ANYARA, har det för första gången blivit möjligt att mäta mängden ANYARA i tumörer som uttrycker 5T4-antigenet,...

Forty-three renal cancer patients, included in a previously concluded multi-centre open label Phase II study (1) of Active Biotech's TTS CD2, were treated with individualized doses of TTS CD2. All...

STOCKHOLM, Sweden, Sept. 29, 2005 (PRIMEZONE) -- Survival data for renal patients and the first generation (TTS CD2) of ANYARA will be presented at the NCRI (National Cancer Research Institute)...

STOCKHOLM, Sweden, Sept. 29, 2005 (PRIMEZONE) -- In an ongoing clinical Phase I study, specific tumor localization of Active Biotech's candidate drug ANYARA, has now been objectively confirmed.Using...

Forty-three renal cancer patients, included in a previously concluded multi-centre open label Phase II study (1) of Active Biotech's TTS CD2, were treated with individualized doses of TTS CD2. All...

Fyrtiotre njurcancerpatienter, vilka ingick i en sedan tidigare avslutad, öppen, multi-center fas II-studie (1) av Active Biotechs TTS CD2, behandlades med individuella doser av TTS CD2. Samtliga...

Using Positron Emission Tomography (PET) and radioactively labeled ANYARA, drug concentrations in tumor and normal tissues of individual patients have been measured for the first time, demonstrating...

Genom att använda tekniken Positron Emission Tomography (PET) och radioaktivt inmärkt ANYARA, har det för första gången blivit möjligt att mäta mängden ANYARA i tumörer som uttrycker 5T4-antigenet,...

STOCKHOLM, Sweden, Sept. 27, 2005 (PRIMEZONE) -- The safety data from Active Biotech's (Stockholm:ACTI.ST) recently concluded clinical phase II safety study shows that laquinimod, a novel oral...